Document is current

Article History

Received: 9 December 2024

Accepted: 20 February 2025

First Online: 26 March 2025

Declarations

:

: This study was approved by sites’ institutional review board.

: Lena M. Unterrainer reports funding from Bavarian Cancer Research Center (BZKF) and from the Munich Clinician Scientist Program (MCSP). She reports fees from Novartis (speaker), Telix (consultant) and Astellas Pharma Inc. (speaker) outside of the submitted work. Jeremie Calais acknowledged grant support from the Prostate Cancer Foundation (PCF). Jeremie Calais reports grants from support to his institution from Lantheus, Novartis, and POINT biopharma. He also reports Consulting activities (advisory boards, speaker, blinded reader) for Advanced Accelerator Applications, Amgen, Astellas, Bayer, Blue Earth Diagnostics Inc., Curium Pharma, Coretag, DS Pharma, Fibrogen, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals, Monrol, Lightpoint medical, Lantheus, Novartis, Nucleus Radiopharma, Pfizer, POINT biopharma, Progenics, Radiomedix, Radiopharm Theranostics, Sanofi, Siemens-Varian, SOFIE, Telix Pharmaceuticals, outside of the submitted work. Johannes Czernin reports the following disclosures: Sofie Biosciences (Founder) Trethera Corporation (Founder), Atkis Oncology (Medical Advisory Board). Thomas Hope has grant funding to the institution from Bayer, Clovis Oncology, GE Healthcare, Lantheus, Janssen, Novartis, Telix Pharmaceuticals, the Prostate CancerFoundation, and the National Cancer Institute (R01CA235741 and R01CA212148). He received personal fees from Bayer, Cardinal Health, BlueEarth Diagnostics, Lantheus, RayzeBio, Sanofi and received fees from and has an equity interest in Curium and AdvanCell. Louise Emmett reports the following disclosures: Advisory board: Novartis, Astellas, Clarity, Advancell and Trial support from: PCF challenge, Movember, Clarity, Novartis, St Vincent's Clinic foundation. The authors have no disclosures or conflicts of interest to declare relevant to this work.